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This study  was  aimed  to compare  the  relative  activities  of  the  puriﬁed  pomegranate  peels
polyphenols  (PPPs)  with  some  other  plant  polyphenols  including  punicalagin,  ellagic  acid,
gallic acid,  phlorizin,  and epigallocatechin  gallate  (EGCG)  on the lipid  metabolism  regula-
tion, and the  cholesterol  efﬂux  mechanisms  of  PPPs  and  punicalagin  were  also  investigated.
In  this  paper,  a convenient  and  accurate  in vitro HL7702  steatosis  hepatic  cell  model  was
applied  to evaluate  the  lipid-lowering  effects  of the  tested  polyphenols.  The  results  showed
that PPPs  possessed  the  strongest  lipid-lowering  effects.  Prevention  group  (treated  with
polyphenols  when  establishing  of  steatosis  model)  was  more  effective  than  treatment  group
(treated with  polyphenols  after  establishment  of  steatosis  model).  Punicalagin  displayed
the strongest  lipid-lowering  effects  among  all the tested  components  of  pomegranate  peel
polyphenols.  Moreover,  PPPs  and  punicalagin  (10, 20,  40 g/mL)  signiﬁcantly  increased
the  mRNA  expression  of  LXR  (Liver  X  receptor  alpha)  and  its target  genes-ABCA1  (ATP-eywords:
omegranate peel polyphenols (PPPs)
lant polyphenols
epatic cell
ipid-lowering effects
binding  cassette  transporter  A1)  in  a dose-dependent  manner  in  HL7702  steatosis  hepatic
cells. The  high  mRNA  expression  of  LXR  and  ABCA1,  next  to  lovastatin,  was  observed  in
cells treated  with  40 g/mL  of  PPPs.  These  in  vitro  ﬁndings  suggested  that PPPs  might  have
great potential  in the  clinic  treatment  of hyperlipemia.
© 2014  The  Authors.  Published  by  Elsevier  Ireland  Ltd. This  is  an  open  access  article  under
Y-NC-Nolecular  mechanisms the CC  B
. Introduction
Pomegranate (Punica granatum L.), a seeded or granular
pple, is derived from the name Pomum (apple) granatus
grainy) [1,2]. It is one of the most investigated fruits in
ecent  years [3]. Numerous studies show that pomegranate
ruits possess signiﬁcant anti-diabetic, anti-inﬂammatory,
nti-oxidant, anti-tumor, and anti-obesity activities in vivo
nd  in vitro [4–6]. Consumption of pomegranate is of great
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beneﬁts to patients with metabolic syndrome, such as coro-
nary  heart disease, diabetes, and hyperlipidemia [7,8]. It
has  reported that consumption of pomegranate juice is able
to  decrease oxidative stress in serum and the macrophage
uptake of oxidized low-density lipoprotein (ox-LDL) of dia-
betic  patients [9].
Pomegranate fruits consist of carbohydrates, minerals,
crude ﬁbers, vitamin C, and considerable varieties of phe-
nolic  compounds, including anthocyanins (3-glucosides
and 3, 5-diglucosides of delphinidin, cyanidin, and
pelargonidin), ellagic acid (EA), gallic acid (GA), punicalin,
punicalagin, pedunculagin, and different ﬂavanols [5,10].
There  are abundant phenolic compounds, punicalagin, EA
cess article under the CC BY-NC-ND license (http://creativecommons.org/
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and GA in the pomegranate peels, and they have known as
natural  antioxidants [11]. Pomegranate shows potent anti-
atherosclerotic activity which could be attributed to the
abundant contents of polyhenols. Punicalagin is the most
abundant polyphenols, and it presents in two anomers:
punicalagin A and B, [6,11–14]. Studies have shown that
punicalagin has antioxidant, antifungal and antibacterial
properties [2]. Ellagic acid has also been demonstrated to
reduce  white fat deposits and triglycerides accumulation
in the body during regular intake of high-fat diets [15].
In  addition, scientiﬁc researches have suggested that
green tea and plant sterols possess the lipid-lowering
effects, and lower the risk of heart diseases [16–18]. Epi-
gallocatechin gallate (EGCG), the main component of tea
polyphenols, has attracted much attention in recent years.
EGCG  exhibits signiﬁcant lipid-lowering activity in mice
[19,20]. However, there are many questions remaining to
be  answered, such as, which components are the main
bioactive ingredients of PPPs? How they play this role?
Moreover, are the lipid-lowering effects of the bioactive
monomers of PPPs stronger than other common plant
polyphenols? Further studies are required to compare the
lipid-lowering and hepatoprotective effects between PPPs
and  its main components (including punicalagin, EA, GA),
EGCG,  and phlorizin.
In  this study, the lipid-lowering effects of the six
kinds of polyphenols were investigated in vitro simulta-
neously. In order to better understand the lipid-lowering
effects of pomegranate peel polyphenols cholesterol, efﬂux
mechanisms were also investigated. LXR and its target
gene-ABCA1 were known to play an important role in the
cholesterol efﬂux pathway [21–23]. However, the effects
and  putative mechanisms of pomegranate peel polyphe-
nols  on these two genes remains poorly understood. The
present  study investigated the cholesterol efﬂux by eval-
uating  LXR and its target gene-ABCA1, and provided
reference to the effective treatment and prevention of non-
alcoholic  fatty liver diseases and to the decrease in the risk
rates  of hyperlipidemia and cardiovascular diseases.
2. Materials and methods
2.1.  Materials and chemicals
HL7702  human hepatic cells were purchased from
China Center for Type Culture Collection (CCTCC). Puni-
calagin, ellagic acid (EA), gallic acid (GA), phlorizin,
epigallocatechin gallate (EGCG), and lovastatin were
obtained from Sigma–Aldrich (St. Louis, MO,  USA), and
the  purities of all the standards were not less than 98%.
Fetal  calf serum was purchased from Hangzhou Sijiqing
Company. Oil red O dye, insulin, penicillin–streptomycin
solution, trypsin, dimethyl sulfoxide (DMSO), 3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide
(MTT)  were provided by Sigma Chemical Company
(Shanghai, China). Alanine aminotransferase (ALT), aspar-
tate  aminotransferase (AST), total triglycerides (TG), and
total  cholesterol (TC) testing cassette were purchased
from Nanjing Jiancheng Bioengineering Institute (Jiangsu,
China).rts 1 (2014) 945–954
2.2.  Preparation of puriﬁed pomegranate peel extracts
Ripe pomegranates were obtained from Lintong,
Shaanxi province of China. The peel was  separated and
cut  into pieces, then dried, milled into ﬁne powders
and kept in a dessicator overnight before extraction for
polyphenols. The extraction was performed using ethanol
ultrasonic-assisted extraction method. Brieﬂy, 1 g of sam-
ple  was  weighed, extraction solution was then obtained
with ultrasonic power of 120 W,  ethanol concentration of
60%  (v/v), temperature at 60 ◦C, solid–liquid ratio of 1–20,
as  well as ultrasonic extraction time of 30 min. There-
after, the extraction solution was concentrated by rotary
evaporator at 40 ◦C, followed by vacuum freeze-drying to
obtain  crude extracts of pomegranate peel polyphenols.
The crude extracts were dissolved in water, extracted by
equal  volume of petroleum ether and the aqueous phase
was  collected. The aqueous phase was then extracted by
equal  volume of chloroform for three times, and aqueous
phase was  collected with pH adjusted to 6.5 by 1 mol L−1
NaOH. The aqueous phase was then extracted by two
times volume of ethyl acetate for three times, and the
ethyl  acetate phase was  collected. Thereafter, the pH of
the  aqueous phase was adjusted to 2.0 by 1 mol  L−1 HCl,
then extracted by two  times volume of ethyl acetate for
three  times. Finally, the six times of extracted acetate phase
were  merged together, the solvent was removed using a
vacuum  rotary evaporator at 40 ◦C, followed by vacuum
drying to obtain the puriﬁed polyphenols obtained from
pomegranate peel extracts.
2.3.  HPLC analysis of the puriﬁed polyphenols extracts
The identiﬁcation of phenolic compounds in the
pomegranate peel polyphenols puriﬁed extracts was per-
formed  by HPLC. The analysis was carried out using a
ZORBAX SB-C18 chromatographic column (4.6 mm i.d.
×250  mm,  5 m,  Agilent, American) on a 1525 Waters HPLC
system equipped with an UV detector (Waters, USA). A
gradient  elution was performed by varying the propor-
tion of solvent A (water containing 1% glacial acetic acid)
and  solvent B (methanol). The g–radient program was as
follows: 0–70 min from 5% to 44% methanol; 70–80 min
with  44% methanol. The ﬂow rate of the mobile phase was
1  mL/min; the UV detection wavelength was  280 nm,  the
sample  injection volume was 20 L, and the column tem-
perature was 30 ◦C.
2.4.  Culture of HL7702 hepatic cells
Cells were kept at 37 ◦C, 95% air, 5% CO2 in RPMI-
1640 supplemented with 10% (v/v) FCS, 100 U/mL penicillin
and  100 g/mL streptomycin. Every 2 days, medium was
refreshed, at 75–80% conﬂuence; cells were split to a new
75  cm2 ﬂask.
2.5.  Building of steatosis hepatic cell modelCells were seeded in 6-well tissue culture plates
(Jetbioﬁl, Guangzhou) at a cell density of 2 × 105 in
1000 L/well and then incubated for 12 h with 10% (v/v)
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BS-PRMI 1640 medium till 20–30 conﬂuence. Subse-
uently, cells were exposed to 10% FBS-RPMI (Fetal Bovine
erum-Roswell Park Memorial Institute) 1640 medium
M1  medium) and 50% FBS-RPMI 1640 medium (M2
edium), respectively. After 24, 48, 72 h, the accumula-
ion of orange red droplets were determined using oil red O
taining,  a vital lipophilic dye used to label fat accumulation
n the cytosol. Contents of AST, ALT, TG, and TC were tested
y  the testing cassette to evaluate the lipid accumulation
evel and damage degree of HL7702 hepatic cell.
.6. MTT  assay for optimum concentration of
olyphenols
The stock solution of all the tested polyphenols, PPPs,
unicalagin, EA, GA, phlorizin, EGCG, lovastatin (positive
ontrol), was achieved by dissolving the solid samples in
imethylsulfoxide (DMSO) at a concentration of 10 mg/mL
nd  then further diluted appropriately with 1640 medium
o  concentration from 160 to 5 g/mL.
This MTT  assay was divided into four groups: nor-
al  group (control group), model group (steatosis cells),
reatment group, and prevention group. Firstly, HL7702
uman hepatic cells were seeded in the 96 well tissue
ulture plates at a cell density of 1000 in 100 L/well.
fter 12 h incubation, normal group and treatment group
ere  exposed to M1  medium, model group exposed to M2
edium,  while prevention group exposed to M2  medium
ith  polyphenols concentration gradient (5, 10, 20, 40, 80,
60  g/mL respectively); 48 h later, normal group, model
roup, and treatment group were exposed to M1  medium,
hile prevention group exposed to M1  medium with
he  same polyphenols concentration gradient. Thereafter,
TT  assay was conducted. The cells exhibiting blue for-
azan/endosomes or needle-like formazan/crystals were
onsidered as reactive cells, whereas the ones with-
ut displaying formazan/endosomes or formazan/crystals
ere labeled as non-reactive cells. Cell viability was
xpressed as a percentage of absorbance values in testing
roup to that in control group, which was considered as
00%.
.7.  Evaluation of lipid-lowering effects of tested
olyphenols
HL7702 cells were seeded in 6-well tissue culture plates
t  a cell density of 2 × 105 in 1000 L/well and then incu-
ated for 12 h with M1  medium till 20–30 conﬂuence.
hereafter, normal group, model group, treatment group,
nd  prevention group cells were treated with the optimum
olyphenols concentration determined by MTT  experi-
ent  above. Finally, oil red O staining, contents of AST, ALT,
C  and TG testing experiment were conducted.
.8. Oil red O staining
Cell  monolayers were ﬁrstly washed twice with phos-
hate buffer saline (PBS, pH 7.0) and were ﬁxed with 4%
m/v)  paraformaldehyde for 5 min, then were washed with
BS  and were ﬁxed with propanediol for 5 min. Thereafter,
onolayers were incubated for 15 min  with 0.5% (m/v)rts 1 (2014) 945–954 947
at  60 ◦C, and then washed with 85% (v/v) propanediol for
5  min. Finally, the monolayers were washed with PBS; the
accumulation of orange red droplets of different groups
was  determined by ordinary light of inverted ﬂuorescence
microscope (Leica DMIRB, Germany).
2.9. Measurement of TG, TC, ALT, and AST contents
After treatment, cell culture medium and the cells were
collected, respectively. ALT and AST contents of the Cell
culture mediums were tested according to the methods
of  ALT and AST enzyme kit (Nanjing, Jiancheng). TG and
TC  contents in the cells were measured using TG and TC
enzyme  kit (Nanjing, Jiancheng).
2.10. RNA extraction and q-PCR
Punicalagin and PPPs were selected as the tested
polyphenols. Low, middle, high doses (10, 20, 40 g/mL)
were  chosen as the gradient concentration. After cul-
ture,  normal group, model group, treatment group cells
were  collected, and the total RNA was extracted using
the  total RNA kit (Omega, American) according to the
manufacturer’s protocol. The cDNA was  synthesized
from 1 g of RNA using RevertAidTM First Strand cDNA
Synthesis Kit (Fermentas). Primer sequences for PCR are
as  follows: LXR, 5′-TCTGGAGACATCTCGGAGGTA-3′ (for-
ward),  and 5′-GGCTCACCAGTTTCATTAGCA-3′ (reverse);
RXR, 5′-CTCCTCAGGCAAGCACTATG-3′ (forward), and
5′-CAGCTCCGTCTTGTCCATCTG-3′ (reverse); ABCA1, 5′-
GGGAGGCTCCCGGAGTT-3′ (forward), and 5′-GTATAAAA-
GAAGCCTCCGAGCATC-3′ (reverse); GAPDH, 5′-TCA-
TTGACCTCAACTACATGG-3′ (forward), and 5′-AAATGA-
GCCCCAGCCTTCTCC-3′ (reverse). The real-time PCR (Step
One  Plus, Applied Biosystems, USA) conditions were: 30 s
at  95 ◦C, followed by 40 cycles of 95 ◦C for 5 s, 58 ◦C for
30 s, and 58 ◦C for 30 s. GAPDH was used as the control in
the  comparative CT method.
2.11.  Statistical analysis
Experiments  were performed at least in triplicate. The
data  in this study are expressed as mean ± SD. One-way
analysis of variance (ANOVA) was  performed using SPSS
software. A probability of p < 0.05 was  considered as signif-
icant.
3.  Results
3.1. HPLC analysis for polyphenols composition of PPPs
The  major polyphenols were identiﬁed and quantiﬁed
by HPLC as shown in Table 1. Components of polyphenols
of the puriﬁed pomegranate peel extracts were identiﬁed
in  the following order: gallic acid (9.97 min), punicalagin
including two  peaks (Isomers, 15.22 and 22.49 min), cate-
chin  (26.65 min), chlorogenic acid (31.53 min), caffeic acid
(35.75  min), epicatechin (41.36 min), rutin (68.60 min), and
ellagic  acid (70.86 min). In the present study, linear regres-
sion  was used for the calculation, and the assay showed
excellent linearity with the correlation coefﬁcients (R2) in
948 W.  Zhao et al. / Toxicology Reports 1 (2014) 945–954
Table 1
Calibration curves and the contents of the identiﬁed polyphenols obtained from the pomegranate peel extracts by HPLC.
Component tR (min) Linearity (g/mL) Regression equation (Y = aX + b) R2 Content (mg/100 mg)
Gallic acid 9.97 ± 0.09 22–110 Y = 5443X + 422.17 0.9991 2.53
Punicalagin 15.22 ± 0.09
22.49 ± 0.08
11–500 Y = 2898X − 1121.61 0.9989 65.38
Catechin 26.65 ± 0.05 22–110 Y = 2031X + 447.94 0.9992 12.66
Chlorogenic  acid 31.53  ± 0.07 1.4–110 Y = 4728X + 156.11 0.9993 0.37
Caffeic acid 35.75 ± 0.09 0.04–80 Y = 8734X + 313.97 0.9987 0.03
Y = 
Y = 
Y = Epicatechin 41.36 ± 0.04 2.2–110 
Rutin 68.60 ± 0.06 2.8–110 
Ellagic acid 70.86 ± s0.08 11–275 
the range of 0.9987–0.9994. Punicalagin, with the level of
65.38  mg/100 mg,  was identiﬁed to be the dominant com-
ponent  of PPPs, followed by catechin, ellagic acid, gallic
acid,  epicatechin, chlorogenic acid, rutin, and caffeic acid
at  the concentration of 12.66, 2.93, 2.53, 0.99, 0.37, 0.34,
and  0.03 mg/100 mg,  respectively.
3.2.  Evaluation of the established steatosis hepatic model
The  oil red O staining results of normal group and model
group were presented in Fig. 1. Cell edges in normal group
were  clear, the accumulation of orange red droplets of
normal  group was evidently less than model group, and
it  was not increased within the modeling time. Whereas,
after modeling, morphological observations showed that
the  orange red droplets were accumulated.
Additionally, contents of TG and TC increased over time
as  shown in Fig. 2A and B. Although there were no signiﬁ-
cant  changes of TG and TC contents at 24 h after modeling,
Fig. 1. Changes of the accumulation of orange red droplets with modeling time 
and  72 h, respectively; B1, B2, and B3 represent the modeling time of model grou1684X + 145.86 0.9994 0.99
1890X + 242.67 0.9990 0.34
2491X − 320.39 0.9992 2.93
the  signiﬁcant change was shown at 48 and 72 h, as com-
pared with normal group (p < 0.01).
Moreover,  AST and ALT contents were observed in
Fig.  2C and D. Compared with normal group, AST and
ALT  contents in cultural supernatants were increased dra-
matically  after modeling for 24 h (p < 0.05), 48 and 72 h
(p  < 0.01).
3.3. Optimum dose of the tested polyphenols
Cell survival rate of all the treatment and preven-
tion groups decreased as the polyphenols concentration
increased as presented in Fig. 3. When the concentration
of the polyphenols ranged 0–10 g/mL, no signiﬁcant cell
survival rates were observed in all the groups; 20 g/mL
polyphenols signiﬁcantly (p < 0.05) decreased cell survival
rate  in GA and phlorizin groups (Fig. 3D and E); treat-
ment with 40 g/mL and 80 g/mL polyphenols resulted
in signiﬁcant (p < 0.05) decreases in cell survival rate of
increasing, where A1, A2, and A3 represent the control group, 24 h, 48 h,
p, 24 h, 48 h, and 72 h, respectively.
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A, phlorizin, EGCG, lovastatin groups (Fig. 3D–F). How-
ver,  there was no signiﬁcant difference in punicalagin,
A and PPPs groups, suggesting that the toxicity of puni-
alagin, EA, and PPPs was lower to cells, as compared with
ther  polyphenols. Cell survival rate of all the groups con-
istently  remarkably (p < 0.01) decreased, when cells were
xposed  to 160 g/mL polyphenols. Therefore, 10 g/mL
as  selected as the appropriate concentration in the fol-
owing  experiments.
.4.  Comparison of the lipid-lowering effects
Treatment or prevention with 10 g/mL polyphenols
punicalagin, EA, PPPs, GA, phlorizin, EGCG, and lovas-
atin) resulted in signiﬁcant decreases in the accumulation
f orange red droplets, indicating that all these tested
olyphenols possessed lipid-lowering effects as presented increasing, respectively; C and D represent the changes of ALT and AST
 means ± SD (n = 4). *p < 0.05 and **p < 0.01 as compared to normal group.
in  Fig. 4. The accumulation degree of orange red droplets
of  the prevention group declined more evident than the
treatment group, suggesting that the lipid-lowering effects
of  the prevention group were stronger than the treatment
group. Furthermore, orange red droplets accumulation of
punicalagin, PPPs, EGCG, and lovastatin groups were less
than  other groups. These results indicated that punicala-
gin, PPPs, EGCG, and lovastatin were more effective as the
lipid-lowering agents than other tested polyphenols.
To further strengthen the above results, TG and TC
contents were tested. As presented in Fig. 5A and B, the
contents of TG and TC of model group were signiﬁcantly
(p < 0.001) higher than that of normal group. When com-
pared  with model group, TG and TC levels of punicalagin,
EA, PPPs, phlorizin, EGCG, and lovastatin groups decreased
signiﬁcantly, indicating that all tested polyphenols pos-
sessed  lipid-lowering effects, which was consistent with
the  results in Fig. 4.
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Fig. 3. Determination of the appropriate concentration of the tested polyphenols by MTT. All values are expressed as means ± SD (n = 4), A, B, C, D, E, F, and
G  represent the change of cell viability of punicalagin, EA, PPPs, GA, phlorizin, EGCG and lovastatin groups with the concentration increasing of polyphenols,
respectively.  *p < 0.05 and **p < 0.01 as compared to normal group (polyphenols’ concentration of treatment group = 0 g/mL). #p < 0.05 and ##p < 0.01 as
compared  to normal group (polyphenols’ concentration of prevention group = 0 g/mL).
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Additionally, there were no signiﬁcant differences in
G  and TC contents of PPPs and EGCG groups, as com-
ared with normal group, which suggested that TG and TC
ontents  in PPPs and EGCG groups returned to normal level.
oreover, when compared with positive control group, no
igniﬁcant  changes of TG and TC level of PPPs and EGCG
roups, indicating that lipid-lowering effects of PPPs and
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ig. 5. A and B represent the changes of TG and TC contents exposed to different
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3.5. Comparison of the hepatocytes damage alleviating
effects
ALT and AST contents in the cultural supernatants of
model group were signiﬁcantly (p < 0.001) higher than that
in  normal group as shown in Fig. 5C and D. When com-
pared with model group, AST and ALT contents in cultural
supernatants of groups were all signiﬁcantly (p < 0.001)
 types of plant polyphenols, respectively; C and D represent the changes
ively. All values are expressed as means ± SD (n = 4). *p < 0.05, **p < 0.01,
s compared to model group.
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Fig. 6. Expressions of LXR, RXR, and ABCA1 of each group of HL7702
hepatic cells treated with punicalagin and PPPs, respectively. *p < 0.05,
**p  < 0.01, as compared to normal group (LXR). #p < 0.05, ##p < 0.01, as
compared to normal group (ABCA1).
decreased by polyphenols, suggesting that the hepatocytes
damage was alleviated. ALT and AST levels in PPPs and
EGCG  treated cells were not signiﬁcantly changed, as com-
pared  with normal group. This observation indicates that
the  AST and ALT contents of PPPs and EGCG groups returned
to  normal level, and the results further elucidate that PPPs
and  EGCG possessed the strongest liver damage alleviating
effects among all the tested polyphenols. In addition, there
were  no signiﬁcant differences in ALT and AST contents of
PPPs  and EGCG groups as compared with positive control
group, illustrating that the hepatocytes damage alleviating
effects of PPPs and EGCG were approximately approaching
to  lovastatin.
3.6. The cholesterol efﬂux mechanisms of pomegranate
peel polypheols
The  cholesterol efﬂux mechanisms of PPPs and its main
component, punicalagin, were also investigated in this
study.  The mRNA expressions of LXR and ABCA1 were
notably increased after incubating with PPPs and punicala-
gin,  and a dose-dependent manner was shown in the cells
treated  with the polyphenols which ranged from low dose
to  high dose (10, 20, 40 g/mL) as shown in the Fig. 6A
and  B. However, there were no signiﬁcant changes of the
mRNA  expression of RXR (Retinoid X receptor alpha) as
the  results shown in Fig. 6. These results indicated that
LXR  and ABCA1 played an important role in the choles-
terol efﬂux regulation of the cells. Furthermore, when the
concentration of these two tested polyphenols reached to
high  dose (40 g/mL), the mRNA expression of LXR andrts 1 (2014) 945–954
ABCA1  regulated by PPPs showed signiﬁcant enhancement
(p < 0.01), next to positive group.
4.  Discussion
The objective of this study was  to compare the lipid-
lowering effects of pomegranate peel polyphenols with
several other plant polyphenols as well as its cholesterol
efﬂux mechanisms. Lovastatin, which has been widely used
for  lipid-lowering purpose as a hepatoprotective drug, can
reduce  cell death in vitro and protect against the cardiotox-
icity of anthracyclines in vivo [24,25]. It therefore has been
chosen  as the positive control drug in the present study.
The  results indicate that RPMI 1640 medium contained
50% FBS could remarkably increase the accumulation of
lipid  droplets, AST, ALT, TC, and TG contents in a time-
dependent manner. Furthermore, at 48 h, the contents
of AST, ALT, TC and TG were all increased signiﬁcantly
(p < 0.05). Therefore, 48 h was chosen as the appropriate
modeling time.
To  accurately compare the lipid-lowering effects of
pomegranate peel polyphenols with other plant polyphe-
nols,  MTT  experiment were performed to eliminate the
interruptions of the toxicology that different kinds of
polyphenols may  have on the cells. The results revealed
that 10 g/mL could be the appropriate concentration,
since cell viability among different groups was  approxi-
mately the same.
As  part of systematic effort to assess the lipid-lowering
effects of the tested plant polyphenols, both lipid accu-
mulation rate and cholesterol level were analyzed. All the
tested  polyphenols could signiﬁcantly (p < 0.05) decrease
lipid  accumulation in both the treatment group and the
prevention group. Furthermore, compared with model
group, the lipid-lowering effects of the prevention group
were  stronger than that in the treatment group, as well
as  TG, TC AST and ALT levels. These data indicated that
punicalagin, EA, PPPs, GA, phlorizin, and EGCG exhibited
signiﬁcant lipid-lowering and hepatoprotective effects.
Moreover, the contents of TG, TC, AST, and ALT in the pre-
vention group were closer to normal group when compared
with  the treatment group, suggesting that the preven-
tion group was  more effective than the treatment group.
Signiﬁcant difference of TG, TC, AST, and ALT contents
of PPPs group were observed as compared with con-
trol  group (p < 0.05). However, no signiﬁcant differences
in TG, TC, AST, and ALT contents of its main monomer
components, punicalagin, EA, and GA, were noticed when
compared with control group (p > 0.05). This observation
suggested that PPPs (mixture) had stronger lipid-lowering
and hepatoprotective effects than the single composit-
ing monomer components. The stronger lipid-lowering
effects of PPPs were again conﬁrmed when compared
with phlorizin group, which showed no signiﬁcant differ-
ences  in AST, ALT, TC, and TG contents as compared with
the  control group (p > 0.05). Additionally, EGCG exhibited
effective lipid-lowering effects which were approaching to
PPPs  as compared with punicalagin, EA, GA, and phlorizin.
This  complies with the previous studies which reported
that EGCG can effectively reduce the cholesterol contents
[26,27]. When compared with phlorizin, we  found that AST,
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LT, TC, and TG contents of punicalagin and EA groups were
loser  to normal group than phlorizin group. This observa-
ion  suggests that punicalagin and EA possessed stronger
ipid-lowering effects. Contents of AST and ALT in phlorizin
roup were closer to normal group than GA group, indicat-
ng  that phlorizin was more effective than GA as the hepatic
ell  damage alleviating agent. Whereas, contents of TC and
G  of GA group were closer to normal group than phlorizin
roup, indicating that GA exhibited stronger lipid-lowering
ffects than phlorizin. Moreover, the contents of AST, ALT,
C,  and TG of punicalagin group were closer to normal
roup than EA group as compared with EA group, sug-
esting that punicalagin possessed stronger lipid-lowering
ffects than EA. Finally, when the lipid-lowering effects
f  PPPs were compared with EGCG, contents of AST and
LT  of PPPs and EGCG prevention group were 4.13, 5.22
nd  4.35, 6.25 U/L, respectively, which value was close to
ormal  group (4.57, 4.53 U/L) and positive group (4.02,
.44  U/L); TG and TC contents of PPPs and EGCG pre-
ention group were 14.36, 4.16 and 14.39, 4.72 mmol/L
espectively, which also had close value to normal group
12.38,  5.03 mmol/L) and positive control group (14.78,
.99  mmol/L). The above results suggest that PPPs and
GCG  possessed effective lipid-lowering effects approa-
hing to positive drug that can lower the contents of AST,
LT,  TC, and TG of hepatic steatosis cells to almost normal
evel.  In addition, the results show that the lipid-lowering
ffects of the PPPs were slightly stronger than EGCG.
In  order to explore the cholesterol efﬂux mechanisms
f pomegranate peel plyphenols in the cells, PPPs and its
ost  abundant polyphenols – punicalagin were chosen as
he  tested polyphenols. The correlation of LXR, RXR, and
BCA1  regulation with the cholesterol efﬂux was furthere studied polyphenols.
investigated. The relative mRNA expression of both LXR
and  its target genes ABCA1 showed a dose-dependent man-
ner,  suggesting that PPPs and punicalagin could regulate
the  cholesterol efﬂux through increasing mRNA expression
of  LXR and ABCA1. Furthermore, when cells were treated
with  high dose of punicalagin and PPPs, the mRNA expres-
sion  of LXR and ABCA1 of the group treated with PPPs was
closer  to the positive control group. As shown in Fig. 6B,
the  relative mRNA expression of LXR and ABCA1 in cells
treated with PPPs were 2.5 and 2.91, respectively; while
positive group, 2.46 and 2.83, respectively. The result sug-
gested  that PPPs was more effective in the regulation of
the  cholesterol efﬂux related genes-LXR and ABCA1. This
was  consistent with the lipid-lowering effects result above
(Fig.  7.).
In  conclusion, this study highlights the different lipid-
lowering effects of a variety of polyphenols (punicalagin,
EA, PPPs, GA, phlorizin, and EGCG) as well as the choles-
terol efﬂux mechanisms of pomegranate peel polyphenols.
We  found that PPPs and EGCG were the most effective
polyphenols among all the tested samples, which had sim-
ilar  lipid-lowering effects to lovastatin. Furthermore, the
prevention group showed stronger lipid-lowering effects
than  the treatment group. In addition, the lipid-lowering
effects of PPPs were stronger than its main monomer com-
ponents  (punicalagin, EA, and GA). Among the monomer
components, punicalagin was the most effective monomer
at  the lipid-lowering aspects. Although the hepatocytes
damage alleviating effects of phlorizin were stronger than
GA,  the cholesterol-lowering effects of GA were stronger.
The  effective lipid-lowering of PPPs might be attributed
to the combined effects of several monomer components
of polyphenols obtained from pomegranate peels. The
ogy Repo
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cholesterol efﬂux mechanism of PPPs and its main com-
ponent, punicalagin, may  be related with the expression
of LXR and ABCA1. Moreover, LXR and ABCA1 showed
a  dose-dependent manner with tested pomegranate peel
polyphenols. 40 g/mL PPPs could up-regulate LXR and
ABCA1  sufﬁciently, which was next to the positive group.
The  strong lipid-lowering effects of PPPs were consistent
with the results above. These ﬁndings may  not only lead
to  a better understanding of the preventive roles of plant
polyphenols, but also suggest that PPPs may  have more
satisfactory effects in the clinic treatment of hyperlipemia
than its monomer components and EGCG.
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